Telomir Pharmaceuticals, Inc. Common Stock (TELO) — Cash Flow-to-Debt Ratio
Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a Cash Flow-to-Debt Ratio of -0.84x as of December 2025, meaning its operating cash flow of $-1.20 Million could theoretically repay -1% of its total liabilities ($1.43 Million) in one year. See Telomir Pharmaceuticals, Inc. Common Sto working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Telomir Pharmaceuticals, Inc. Common Stock Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for Telomir Pharmaceuticals, Inc. Common Stock across 5 annual periods. Also explore Telomir Pharmaceuticals, Inc. Common Sto annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Telomir Pharmaceuticals, Inc. Common Stock (2021–2025)
Year-by-year debt coverage analysis for Telomir Pharmaceuticals, Inc. Common Stock. For market capitalisation and broader financial context, see Telomir Pharmaceuticals, Inc. Common Sto market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.58x | $-3.69 Million | $1.43 Million | ▲ +65.3% |
| 2024 | -7.45x | $-5.07 Million | $680.97K | ▼ -157.6% |
| 2023 | -2.89x | $-3.86 Million | $1.34 Million | ▼ -508.0% |
| 2022 | -0.48x | $-468.66K | $986.01K | ▲ +45.0% |
| 2021 | -0.86x | $-119.40K | $138.13K | — |